Quilizumab

Generic Name
Quilizumab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1228538-47-3
Unique Ingredient Identifier
26F96HRJ3W
Background

Quilizumab is under investigation in clinical trial NCT01160861 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria

Phase 2
Completed
Conditions
Urticaria
Interventions
Drug: Placebo
Drug: Quilizumab
First Posted Date
2013-11-20
Last Posted Date
2016-11-02
Lead Sponsor
Genentech, Inc.
Target Recruit Count
32
Registration Number
NCT01987947

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: MEMP1972A
Drug: placebo
First Posted Date
2012-04-20
Last Posted Date
2016-11-02
Lead Sponsor
Genentech, Inc.
Target Recruit Count
578
Registration Number
NCT01582503

A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: placebo
Drug: MEMP1972A
First Posted Date
2010-09-08
Last Posted Date
2016-11-02
Lead Sponsor
Genentech, Inc.
Target Recruit Count
29
Registration Number
NCT01196039

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis

Phase 1
Completed
Conditions
Allergic Rhinitis
Interventions
Drug: MEMP1972A
Drug: placebo
First Posted Date
2010-07-12
Last Posted Date
2022-12-12
Lead Sponsor
Genentech, Inc.
Target Recruit Count
36
Registration Number
NCT01160861
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy